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CT-7 = cancer testis-7; HLA = human leukocyte antigen; MHC = major histocompatibility complex; NY-ESO-1 = New York Esophageal-1; SSX =
synovial sarcoma-x; TGF = transforming growth factor.
Available online http://breast-cancer-research.com/content/3/2/095
Introduction
Convincing evidence for immune recognition of cancer in
the autologous host has been provided by the identifica-
tion of human tumor antigens [1,2] and by the verification
of cancer immunesurveillance [3]. Cancer vaccines are a
direct application of this knowledge and are based on the
principle that a rigorous autotumorlytic immune response
can be induced in cancer patients by immunization with
tumor-associated antigens. Successful development of
immunotherapeutic breast cancer vaccines hinges on the
identification of appropriate target antigens and the estab-
lishment of effective immunization strategies, as well as on
our ability to devise methods to circumvent immune
escape mechanisms utilized by the evolving tumor. Prelim-
inary progress in meeting these challenges is being made,
as demonstrated by the ability of cancer vaccines to
induce antigen-specific T lymphocyte responses and
objective clinical responses in cancer patients. Although
the results of recent clinical trials are promising, it should
be noted that these are early-stage vaccine trials involving
small populations of mostly end-stage melanoma patients,
and are subject to variable patient and tumor responses.
Nevertheless, the lessons learned from these studies can
now be applied to the development of therapeutic breast
cancer vaccines.
Target molecules for antigen-specific breast
cancer vaccines
Both immunogenicity in cancer patients and restricted
tissue expression are characteristics used to define anti-
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genic targets for cancer vaccines. Immunological methods
of gene discovery, such as CD8+ and CD4+ T cell
epitope cloning [1,4] and serum antibody expression
cloning (SEREX) [2], have led to the identification of
tissue-restricted tumor antigens that are recognized by the
immune systems of cancer patients and have added to the
list of target antigens applicable to breast cancer
(Table 1). These antigens fall into several categories, such
as differentiation antigens, cancer-testis antigens, ampli-
fied/overexpressed gene products, and mutational anti-
gens. One of the first target molecules to be examined in
the context of a breast cancer vaccine is carcinoembrionic
antigen (CEA), a differentiation antigen of the gut,
expressed exclusively in normal colonic epithelium and
approximately 50% of breast cancers [5]. With regard to
clinical trials, Morse and colleagues have observed objec-
tive responses in patients with metastatic disease, includ-
ing breast cancer, following immunization with dendritic
cells (see below) pulsed with an human leukocyte antigen
(HLA)-A2 restricted peptide of CEA [6]. Recently, a new
differentiation antigen of the breast, NY-BR-1, was identi-
fied by SEREX analysis and was found to be expressed
exclusively in normal testis and breast, as well as in 80%
of breast cancers (Jäger et al, manuscript submitted). NY-
BR-1 is recognized by high titered serum IgG antibodies
present in breast cancer patients, and its ability to induce
a cellular immune response is under investigation.
Cancer-testis antigens represent a group of immunogenic
proteins expressed exclusively in normal germ cells of the
testis and embryonic ovary, and a percentage of various
cancers. The melanoma antigens MAGE, BAGE, and
GAGE are prototype cancer-testis antigens, first identified
by cloning epitopes recognized by CD8+ T lymphocytes of
melanoma patients [1,7]. SEREX analysis has also led to
the identification of cancer testis antigens, including New
York Esophageal-1 (NY-ESO-1), cancer testis-7 (CT-7),
and the synovial sarcoma-x (SSX) family of antigens [8].
The enormous potential of CT antigens as vaccine targets
is based on their restricted expression pattern and their
high frequency of immunogenicity in cancer patients.
Results of recent clinical trials using NY-ESO-1 [9] and
MAGE-3 [10] as target antigens have been promising in
terms of inducing antigen-specific T cells in vivo and, in
some cases, concomitant disease regressions.
Mutated and amplified gene products represent another
group of target antigens. The Her-2/neu oncogene is
amplified in approximately 40% of breast cancers, and Her-
2/neu-specific T cell responses have been observed in
patients vaccinated with major histocompatibility (MHC)
class II binding peptides derived from Her-2/neu [11]. The
p53 tumor suppressor gene is frequently mutated in breast
cancer and is associated with an autologous antibody
response in breast cancer patients [12]. The large number
of different p53 mutations makes targeting mutated p53
epitopes impractical. On the other hand, mutations
increase the cellular half-life of p53, causing it to be overex-
pressed in cancer, indicating that immunization with wild
type p53 may be an alternative. In fact, cytotoxic T lympho-
cyte (CTL) clones reactive against wild type p53 were gen-
erated from precursors present in the peripheral blood
lymphocytes of healthy individuals, and were capable of
lyzing several human tumor cell lines [13]. Three additional
antigens recognized by the humoral immune system of
breast cancer patients, NY-BR-62, NY-BR-85, and tumor
protein D52, were found to be overexpressed in 60%,
90%, and 60% of breast cancers, respectively (Scanlan et
al, manuscript submitted). Their significance in relation to
breast cancer vaccines is being investigated.
Immunization strategies
Target antigens must first be presented as processed
peptides bound to MHC class I and class II molecules.
Recognition of these MHC-peptide complexes on the
surface of antigen presenting cells (APCs) by antigen-spe-
cific T lymphocytes, together with additional co-stimulation,
leads to the proliferation of antigen-specific CD8+ and
CD4+ T cells capable of lytic and immunostimulatory func-
tions. Many antigen-specific cancer vaccines have been
prepared as MHC class I binding peptides and adminis-
tered intradermally, along with adjuvant and cytokines, in
order to enhance uptake by APCs and augment the
immune response. Recently, a MAGE-3 peptide vaccine
Table 1
Potential targets for antigen-specific breast cancer vaccines
and their frequency of mRNA expression,
amplification/overexpression1 or mutation2 in breast cancer
Target antigen Expression in breast cancer Reference
Differentiation antigens
Carcinoembryonic antigen 50% [5]
NY-BR-1 80% [26]
Cancer–testis antigens
NY-ESO-1 24% [27]
MAGE-1 8% [27]
MAGE-3 14% [27]
BAGE 2% [27]
GAGE 8% [27]
SCP-1 31% [27]
SSX-1 12% [27]
SSX-2 8% [27]
SSX-4 14% [27]
CT-7 30% [28]
Amplified/overexpressed antigens
Her2/neu 40%1 [29]
NY-BR-62 60%1 [30]
NY-BR-85 90%1 [30]
Tumor protein D52 60%1 [30]
Mutational antigens
p53 17%2 [31]c
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yielded encouraging clinical results [14]. In this study, 7
out of 25 melanoma patients showed significant tumor
regressions following vaccination, although there was no
evidence of a strong CTL response against the MAGE-3
peptide in these responding patients.
Improvements in the delivery and presentation of target
antigens are ongoing and include such strategies as
continuous antigen administration by lymph node perfu-
sion (Kundig, personal communication), direct targeting
of APCs with recombinant Listeria monocytogenes that
has been engineered to express tumor-associated anti-
gens [15], and dendritic cell (DC) vaccines [16]. DCs
are highly proficient APCs, expressing elevated levels of
MHC class I and class II molecules, as well as important
co-stimulatory molecules, and they also produce a
variety of immunostimulatory cytokines [16]. DCs can be
generated in vitro from precursors present in peripheral
blood and subsequently used to present tumor antigens
in vivo, when pulsed with antigenic peptide or trans-
fected with DNA constructs encoding appropriate anti-
gens. Several clinical trials employing DC vaccines have
been carried out and the results have been promising
[6,11,17]. With regard to epithelial cancers, Murphy and
colleagues used DCs pulsed with HLA-A2 binding pep-
tides derived from prostate-specific membrane antigen
to treat patients with prostate cancer and observed sig-
nificant clinical responses in 8 out of 33 vaccinated
patients [18], and in a subset of these responders,
cytokine secretion and CTL activity was detected against
the immunizing peptide [19].
Current methods of adoptive immunotherapy rely on in vitro
immunization, whereby tumor infiltrating lymphocytes are
harvested from surgical specimens and propagated in vitro
in the presence of interleukin-2 (IL-2) and appropriate
antigen. The resultant CTL clones are then reintroduced
into the autologous patient. Encouraging results have been
obtained with this method as well. In one such study, CTLs
specific for the melanocyte differentiation antigen gp100
were generated by cultivating tumor infiltrating lymphocytes
in the presence of interleukin-2 and gp100. Upon infusion
of these CTLs into autologous melanoma patients, signifi-
cant tumor regressions were observed [20].
Other immunization strategies include the use of DNA vac-
cines, either in the form of viruses (adenovirus, vaccinia
virus) or naked DNA, to deliver genes encoding tumor anti-
gens [21]. Such vectors contain the coding sequence for
a particular target antigen and may also contain
sequences encoding targeting motifs for MHC class I and
class II pathways, immunostimulatory cytokines, and co-
stimulatory molecules. One major concern with using viral
vectors is the presence of neutralizing antiviral antibodies
in the recipient, resulting from a prior immunization (eg
smallpox vaccine), which would negate vaccination.
Circumventing the tumor’s immunological
escape mechanisms
In response to immunesurveillance or effective immuno-
therapy, tumor cells may evolve mechanisms that allow
them to escape immune recognition. Such immunoselec-
tion can cause an outgrowth of tumor cell populations that
have lost expression of a given target antigen [22]. The
use of polyvalent vaccines, specific for several tumor-
associated antigens, or vaccination with antigens required
by the tumor for maintenance of its malignant phenotype
(eg telomerase), may circumvent this form of immune
escape. Tumor cells also secrete immunosuppressive
cytokines such as transforming growth factor (TGF)-b and
IL-10, which can inhibit T lymphocyte effector function.
Animal models have shown that it is possible to block the
inhibitory activity of TGF-b by using an antibody against
TGF-b in conjunction with IL-2 [23]. Similarly, blocking of
inhibitory co-stimulation, such as the interaction between
the CTLA-4 molecule on the surface of activated T cells
and the B7 molecule on APCs, may augment the immune
response [24]. An additional and quite significant form of
immune escape is the ability of tumor cells to evolve
mechanisms that impede antigen processing and presen-
tation. Much attention is currently being focused on the
proteosome, a key component of the antigen processing
pathway, and it is hoped that these studies will generate a
more thorough understanding of antigen presentation,
enabling us to design strategies to thwart this mode of
immune escape [25].
Conclusion
Although active immunotherapy directed against specific
target molecules expressed in cancer offers promise for
cancer treatment, a considerable amount of research
needs to be carried out before it can be considered a
viable therapeutic option. Identification of additional target
antigens will increase the number of individuals that can
be treated with cancer vaccines and allow for the develop-
ment of polyvalent vaccines, which may offset antigen loss
by tumors. Different immunization strategies are the
subject of current immunotherapy trials, and by placing
emphasis on the route of specific immunostimulation
these trials may result in enhanced immune responses and
clinical outcomes. Finally, it is important that patient moni-
toring schemes be enhanced and standardized since it will
allow for improved measurement of patient responses and
direct comparison of different clinical trials.
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